INNOCOLL HOLDINGS PLC
INNOCOLL HOLDINGS PLC (INNL): 5 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.6 months
D/E -3.36 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for INNOCOLL HOLDINGS PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.2M
Quarterly Burn
$7.6M
Runway
3.6 mo
Revenue
$1.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| collaguard | Approved |
| collatampg | Approved |
| regenepro | Approved |
| septocoll | Approved |
| xaracoll | Phase 3 |
Frequently asked questions
How many drug candidates are in INNOCOLL HOLDINGS PLC's pipeline?
INNOCOLL HOLDINGS PLC (INNL) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INNOCOLL HOLDINGS PLC's lead drug candidate?
INNOCOLL HOLDINGS PLC's most advanced tracked candidate is collaguard (Approved) for prevention of post-operative adhesions.
What is INNOCOLL HOLDINGS PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INNOCOLL HOLDINGS PLC has approximately 3.6 months of cash runway.
Get the full picture on INNOCOLL HOLDINGS PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.